Clinical Trials for Lung Cancer: How to Find Studies and Treatment Options

Lung cancer is the leading cause of cancer death in the United States, but the field has seen extraordinary therapeutic progress over the past decade through targeted therapies and immunotherapy, and it continues to evolve rapidly with new molecular targets and treatment combinations. For patients with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), clinical trials for lung cancer can offer access to therapies still under study — sometimes for treatment-resistant disease or rare molecular subtypes. That said, a trial is research first: it is not a guaranteed path to a better treatment. This guide explains what trials are, how the phases work, why biomarker testing matters, how to find studies, and the questions to bring to your oncologist. For a broader overview, see our how to find clinical trials guide and our medical conditions library. Lung cancer affects both people who smoked and those who never did, and this information applies regardless of how the disease arose.

What a clinical trial is (and isn’t)

A clinical trial is a research study that tests whether a treatment is safe and effective in people. Its central purpose is to answer a scientific question, not to deliver a proven therapy to any one patient. In some trials you may be assigned to standard care or, in certain designs, a placebo alongside standard treatment rather than the experimental drug — and there is no promise that participating will improve your outcome. Studies are overseen by an Institutional Review Board (IRB) and follow a written protocol designed to protect participants. Keeping this framing in mind helps set realistic expectations while still recognizing the real value trials can offer.

Understanding trial phases (1 through 4)

Investigational cancer therapies generally move through four phases, as described by the U.S. Food & Drug Administration:

• Phase 1 tests safety, dosing, and side effects in a small group.
• Phase 2 evaluates whether the treatment works for a specific cancer while continuing to monitor safety.
• Phase 3 compares the new treatment against current standard care in a larger population; strong results can support FDA approval.
• Phase 4 studies follow an approved therapy after it reaches the market to track long-term safety and real-world use.

Knowing a trial’s phase tells you how much is already known about the therapy and what the study is primarily trying to learn.

Why biomarker (molecular) testing matters

NSCLC has multiple targetable driver mutations, each with specific drug classes. Comprehensive next-generation sequencing of the tumor identifies which mutations you have and, in turn, which trials are appropriate. Without knowing your tumor’s molecular profile, you cannot be matched to mutation-specific studies. Most academic medical centers perform comprehensive molecular testing as part of a standard NSCLC workup, and NCI materials emphasize the role of biomarker testing in modern lung cancer care.

Common targetable alterations in NSCLC include:

• EGFR (roughly 15–20% of NSCLC; more common in people who never smoked and in some Asian populations)
• KRAS G12C (about 13%; more common in people with a smoking history)
• ALK fusion (about 5%)
• ROS1 fusion (about 1–2%)
• BRAF V600E (about 3%)
• MET exon 14 (about 3%)
• RET fusion (about 1–2%)
• NTRK fusion (rare but actionable)
• HER2 alterations (about 2–3%)

These percentages are approximate and can vary by population; your oncology team will interpret your specific results.

Categories of lung cancer trials

Active lung cancer trials in 2026 include:

Targeted therapy for driver mutations: EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, BRAF V600E, NTRK, HER2, and others, testing next-generation inhibitors, resistance-overcoming agents, and combinations.

Immunotherapy combinations: PD-1/PD-L1 inhibitors combined with chemotherapy or with other immune-targeting agents, in both first-line and later-line settings.

Antibody-drug conjugates (ADCs): ADCs targeting markers such as HER3, TROP2, and MET, particularly after resistance to immunotherapy and targeted therapy.

Bispecific and novel immunotherapies: Agents engaging multiple immune mechanisms simultaneously, including T-cell engagers.

Small cell lung cancer: Historically harder to treat, SCLC now has emerging approaches including DLL3-targeted T-cell engagers and new combinations.

Early-stage adjuvant and perioperative therapy: Trials testing whether immunotherapy or targeted therapy added around surgery improves cure rates.

Screening trials: Studies of new ways to detect lung cancer earlier in high-risk people. Confirm the current status of any specific drug or approach, since the field changes quickly.

Where to find lung cancer trials

Resources for lung cancer trial searches:

• ClinicalTrials.gov — the comprehensive federal registry.
• National Cancer Institute clinical trials search — a curated finder for NCI-supported studies.
• GO2 for Lung Cancer — patient resources and trial navigation.
• American Lung Association — lung cancer research and support resources.
• NCI-Designated Cancer Centers and major academic lung cancer programs, which run the most extensive trial portfolios.

For lung cancer specifically, comprehensive genomic testing of the tumor is essential for trial matching. Bring a study’s NCT identifier (from ClinicalTrials.gov) to your oncologist so you can review eligibility together.

Informed consent and your right to withdraw

Before joining any trial, the study team must take you through informed consent: a clear explanation of the study’s purpose, procedures, duration, potential risks and benefits, the alternatives to participating, and how your privacy is protected. Consent is an ongoing conversation, not just a signature — ask every question, and take the document home to consider if you wish.

Participation is voluntary throughout. You have the right to withdraw at any time, for any reason, without penalty and without losing the regular cancer care you are entitled to. If you decide to leave a study, tell the team so they can help you stop safely and transition your care.

Typical eligibility for lung cancer trials

Common inclusion criteria include a confirmed lung cancer diagnosis with specific histology, a stage matching the trial’s target population, a specific molecular profile (for targeted-therapy trials), a defined performance status (often ECOG 0–2), adequate organ function, measurable disease (for response-based trials), and a specific prior-therapy history.

Common exclusion criteria include active brain metastases (this varies — some trials specifically include CNS disease), other active cancers, significant cardiac disease, significant interstitial lung disease (which can exclude patients from some immunotherapy trials), active autoimmune disease (for some immunotherapy trials), and pregnancy. Every protocol sets its own rules, so eligibility is decided study by study.

Trials for treatment-resistant disease

Patients whose cancer has progressed on standard therapies often have a strong case for trial participation. Common scenarios include EGFR-mutant NSCLC after progression on osimertinib (studies of HER3-targeted ADCs, MET-inhibitor combinations, and chemotherapy combinations); KRAS G12C-mutant NSCLC after progression on a first-generation inhibitor (newer inhibitors and combinations); NSCLC after immunotherapy and chemotherapy (ADCs and novel combinations); and SCLC after platinum-based chemotherapy (DLL3-targeted T-cell engagers and other approaches). Which options apply depends on your tumor’s profile and treatment history.

Adjuvant and perioperative trials

Early-stage lung cancer trials test whether systemic therapy added around surgery improves outcomes. Examples include adjuvant targeted therapy for resected molecularly defined NSCLC, adjuvant immunotherapy in eligible patients, and neoadjuvant (pre-surgery) immunotherapy combinations. For patients with resectable lung cancer, these trials may offer access to strategies aimed at improving cure rates.

What participation involves

Lung cancer trials typically involve a comprehensive baseline workup (CT/PET imaging, brain MRI, labs, ECG, pulmonary function tests, and a tumor biopsy if needed); treatment with the experimental therapy alone or in combination, often in cycles every few weeks; imaging assessments every 6 to 12 weeks to evaluate response; close monitoring for side effects; and long-term follow-up. For metastatic disease, treatment usually continues until progression, intolerable toxicity, or another stopping point; adjuvant trials are usually time-limited with extended follow-up.

Talk to your oncologist first — and don’t stop treatment on your own

The most important safety point: do not stop or change your current cancer treatment to qualify for a trial without first discussing it with your oncologist. Timing between therapies (the “washout” period) is carefully managed in cancer care, and stopping treatment prematurely can be harmful. Your oncologist can help you interpret your biomarker results, identify appropriate studies, coordinate with the research team, and weigh a trial against other proven options. A trial is best considered as one part of a comprehensive, clinician-guided treatment plan.

Lung cancer screening — including for high-risk people

Beyond treatment trials, screening research is active, and screening itself saves lives in the right population. Current recommendations from the U.S. Preventive Services Task Force (2021) call for annual low-dose CT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and currently smoke or quit within the past 15 years. Screening is a shared decision that includes counseling on its benefits and harms, and it is not a substitute for quitting smoking. Research studies are also testing blood-based early-detection tests, better risk stratification, and ways to reduce false positives. If you think you may be eligible for screening, ask your primary care provider.

Frequently Asked Questions

Do I need molecular testing before considering trials?

For NSCLC it is strongly recommended. Comprehensive genomic profiling identifies which trials are appropriate, and most academic centers perform it as standard care. SCLC trials are typically less mutation-specific.

Are lung cancer trials only for patients without standard options?

No. Trials enroll across all stages and treatment lines. First-line trials test whether new therapies improve on existing ones, adjuvant trials test post-surgery interventions, and trials for treatment-resistant disease are common but not the only category.

Can I participate if I have brain metastases?

It depends on the trial. Some exclude patients with active brain metastases; others specifically target this population, and treated, stable brain metastases are sometimes accepted. A brain MRI is part of most trial workups.

Does lung cancer only affect smokers?

No. While smoking is the biggest risk factor, a meaningful share of lung cancers occur in people who never smoked — often driven by targetable mutations such as EGFR. Lung cancer is a disease that deserves compassion and prompt care regardless of smoking history.

Do I need to travel for lung cancer trials?

Sometimes. Some studies run at many sites; trials in rare molecular subtypes are often concentrated at a few academic centers. For common settings, local academic medical centers usually have several trial options.

The bottom line on lung cancer trials

Lung cancer is among the most actively researched cancers, with remarkable progress in targeted therapy and immunotherapy. Comprehensive biomarker testing is essential for matching to mutation-specific trials, and NCI-Designated Cancer Centers offer the most extensive programs. Remember that a trial is research, not guaranteed treatment; informed consent and your right to withdraw are yours throughout; and you should never stop your current therapy to qualify without your oncologist’s guidance. Discussed thoughtfully with your care team — and with your tumor adequately profiled — a trial can be a valuable option within a comprehensive treatment plan.

Sources

• ClinicalTrials.gov (U.S. National Library of Medicine / NIH) — trial registry and participant information
• National Cancer Institute (NCI) — clinical trials search, biomarker/molecular testing, and lung cancer treatment overviews
• U.S. Preventive Services Task Force (USPSTF) — 2021 lung cancer screening recommendation (annual low-dose CT for eligible adults)
• U.S. Food & Drug Administration (FDA) — clinical trial phases and the drug-development process